ALZ-101 vs AV-1959R

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Alzheimer's Disease

Shared mechanism: Amyloid-beta · full Alzheimer's Disease pipeline

ALZ-101

Developed by Alzinova AB

Phase 1 in Alzheimer's DiseaseBiologic (active vaccine)
Partial signal

NCT05328115 · Phase 1 · completed

Most of the trial was randomized and blinded against placebo, but the highest-dose group was given openly rather than blinded, and only 33 people took part. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Reports Part A of the trial (26 randomised participants), fewer than the trial's registered enrollment of 33.

Reported efficacy

Number of adverse events (AEs) and serious AEs (SAEs) (From enrolment through study completion, an average 1 year); Number of participants with treatment-emergent AEs and SAEs (From enrolment through study completion, an average 1 year); Number of AEs of special interest (AESIs), including injection-related events (IREs)and amyloid-related imaging abnormalities (ARIAs) (From enrolment through study completion, an average 1 year); Number of participants with clinically significant cognitive or functional worsening of Alzheimer's Disease(AD) according to Alzheimer's DiseaseCooperative Study -Clinician's Global Impression of Change (ADCS-CGIC)scores of 6 and 7 (From first dose to study completion, an average 1 year): Part A of the phase 1b trial of the anti-amyloid-oligomer vaccine ALZ-101 in early Alzheimer's disease: participants were randomised to receive placebo (n = 6), 125 micrograms (n = 10) or 250 micrograms (n = 10) of ALZ-101. The study met its primary and secondary endpoints, the vaccine was well tolerated, there were no cases of suspected meningoencephalitis or ARIA-E, and the vaccine proved immunogenic with oligomer-specific antibody titres evolving after three administrations. (met)

Result source: NCT05328115

AV-1959R

Developed by Nuravax, Inc.

Phase 2 in Alzheimer's DiseaseBiologic (active vaccine)
Weak signal

NCT06831812 · Phase 1 · completed

The trial was randomized and blinded with a placebo comparator, but it enrolled only 16 people in total, with as few as two per placebo group, and it was designed to test safety and antibody response rather than a disease outcome. No serious adverse events occurred in any group, but the very small numbers mean the safety comparison cannot rule much out. Its registered primary outcome on ClinicalTrials.gov is "Safety and Tolerability of AV-1959R Compared to Placebo". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

Next expected readout: October 2029 · NCT07827768 (registry estimate)

Reported efficacy

Safety and Tolerability of AV-1959R Compared to Placebo (Up to 26 weeks): Safety and Tolerability of AV-1959R Compared to Placebo (Up to 26 weeks): Arm 1: AV-1959R (100 µg) + Adjuvant - Cohort 1 — Participants with ≥1 TEAE: 5 Participants; Participants with ≥1 SAE: 0 Participants | Arm 2: Placebo (Adjuvant Only) - Cohort 1 — Participants with ≥1 TEAE: 1 Participants; Participants with ≥1 SAE: 0 Participants | Arm 3: AV-1959R (300 µg) + Adjuvant - Cohort 2 — Participants with ≥1 TEAE: 6 Participants; Participants with ≥1 SAE: 0 Participants | Arm 4: Placebo (Adjuvant Only) - Cohort 2 — Participants with ≥1 TEAE: 2 Participants; Participants with ≥1 SAE: 0 Participants (not_applicable)

Result source: NCT06831812

Results for Alzheimer's Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointALZ-101AV-1959R
CDR-SB, change—Not reported—Not reported
ADAS-Cog11, change—Not reported—Not reported
ADCS-ADL, change—Not reported—Not reported
MMSE, change—Not reported—Not reported
Amyloid PET, change (centiloids)—Not reported—Not reported

CDR-SB, change

ALZ-101
—Not reported
AV-1959R
—Not reported

ADAS-Cog11, change

ALZ-101
—Not reported
AV-1959R
—Not reported

ADCS-ADL, change

ALZ-101
—Not reported
AV-1959R
—Not reported

MMSE, change

ALZ-101
—Not reported
AV-1959R
—Not reported

Amyloid PET, change (centiloids)

ALZ-101
—Not reported
AV-1959R
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

ALZ-101: no structured comparison results are available for Alzheimer's Disease.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. ALZ-101: 0 of 4 rows · AV-1959R: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricAV-1959R
Dropout rate
0%300 µg + Adjuvanta
NCT06831812 · Phase 1 · combination
show 1 more result
0%100 µg + Adjuvant
NCT06831812 · Phase 1 · combination
Discontinued due to AEs
—300 µg + Adjuvanta
NCT06831812 · Phase 1 · combination
show 1 more result
—100 µg + Adjuvant
NCT06831812 · Phase 1 · combination
Serious AEs
0%300 µg + Adjuvanta
NCT06831812 · Phase 1 · combination
show 1 more result
0%100 µg + Adjuvant
NCT06831812 · Phase 1 · combination
Most frequent reported AEs
300 µg + Adjuvanta
injection site pain 100% (placebo 50%)
NCT06831812 · Phase 1 · combination
show 1 more result
100 µg + Adjuvant
injection site pain 83.3% (placebo 50%)
NCT06831812 · Phase 1 · combination

Notes

  1. aPopulation comparability has not been reviewed for these studies.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ALZ-101's landscape · AV-1959R's landscape